Author:
López-Gil Juan Ignacio,Lubiano María Asunción
Publisher
Springer International Publishing
Reference13 articles.
1. Cefalu WT, Buse JB, Del Prato S, Home PhD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC (2014) Beyond Metformin: safety considerations in the decision-making process for pelecting a second medication for type 2 diabetes management. Diabetes Care 37:2647–2659
2. Cernea S (2016) Heart failure and chronic kidney disease in type 2 diabetes. J Interdisc Med 1(3):252–258
3. Chin MP, Wrolstad D, Bakris GL, Chertow GM, De Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ (2014) Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Cardiac Fail 20(12):953–958
4. Davie M, Chatterjee S, Khunti K (2016) The treatment of type 2 diabetes in the presence of renal impairment: What we should know about newer therapies. Clin Pharm: Adv and Appl 8:61–81
5. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim S-Y, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37(27):2105–2114